Healthcare providers can remain slow to intensify type 2 diabetes medication even after making the jump to basal insulin, with consequences for glycemic control and potentially cardiovascular risk, study results show.
06-14-2020 | ADA 2020 | Conference coverage | News
Hospitalized people with poorly controlled type 2 diabetes who are treated with insulin glargine U300 have comparable glycemic control to those given the U100 formulation, and may have a lower risk for hypoglycemia, researchers report.
People with type 2 diabetes who are treated with metformin prior to undergoing major surgical interventions may have better postoperative outcomes than those without exposure to the drug, researchers report.
Although helpful for primary care physicians, a type 2 diabetes treatment decision support tool may be missing the point for most people with poorly controlled glucose levels, suggest findings from a pilot study.
Improving how type 2 diabetes care is used and delivered may be more important to achieving glycemic control than addressing inflexible patient and clinical characteristics often considered in clinical practice, researchers have discovered.
A reassuring UK study has found limited evidence to suggest non-White patients are at a disadvantage for being diagnosed with type 2 diabetes in primary care and having their cardiometabolic risk managed around the time of initial diagnosis.
Giving people with type 2 diabetes “wear-and-forget” masked flash glucose monitoring to allow their healthcare providers access to detailed glucose profiles is feasible in primary care, but it is not clear how beneficial this is, show the results of the GP-OSMOTIC trial.
Improvements in cardiovascular risk factors remain 5 years after the end of intensive multifactorial treatment of people newly diagnosed with type 2 diabetes in the ADDITION-Europe trial, report the investigators.